Metabolic Syndrome, Obesity and Inflammation

biyomedikalozel5-1-24kapak

Koray ATİLAa
aDokuz Eylül University Faculty of Medicine, Department of General Surgery, İzmir, Türkiye

Atila K. Metabolic syndrome, obesity and inflammation. In: Koçdor H, Pabuççuoğlu A, Zihnioğlu F, eds. İnflammation and in vitro Diagnostics. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.89-93.

Article Language: EN

ABSTRACT
Obesity is recognized as a serious public health problem, as it increases the risks of multiple diseases, such as diabetes, heart disease, high blood pressure, and some cancers. Metabolic syndrome consists of several metabolic abnormalities, including intraabdominal obesity, hyperglycemia, and hypertension. Inflammation is a natural part of the immune system and is the body’s natural defensive response to many harmful, foreign and destructive effects. However, when inflammation develops against its tissues, chronic inflammation develops. Obesity causes low-grade chronic inflammation. Adipose tissue is one of the most important endocrine organs and it releases many inflammatory mediators such as Interleukin-1, Interleukin-6, Tumor Necrosis Factor-α, C-Reactive Protein and adipokines like adiponectin. Obese people have higher circulating concentrations of many inflammatory markers than lean people, and these are believed to play a role in causing insulin resistance and metabolic syndrome.

Keywords: Obesity; metabolic syndrome; inflammation

Referanslar

  1. Agha M, Agha R. The rising prevalence of obesity: part A: impact on public health. Int J Surg Oncol (N Y). 2017;2(7):e17. [Crossref]  [PubMed]  [PMC]
  2. Jaacks LM, Vandevijvere S, Pan A, F, et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 2019;7(3):231-40. [Crossref]  [PubMed]
  3. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2017;16(390):2627-42.
  4. Schetz M, De Jong A, Deane AM, et al. Obesity in the critically ill: a narrative review. Intensive Care Med. 2019;45(6):757-69. [Crossref]  [PubMed]
  5. Frank Q Nuttall. Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutr Today. 2015;50(3):117-28. [Crossref]  [PubMed]  [PMC]
  6. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607. [Crossref]  [PubMed]
  7. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. American Journal of Medicine. 2006;119(10):812-9. [Crossref]  [PubMed]
  8. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-56. [Crossref]  [PubMed]
  9. Staiano AE, Katzmarzyk PT. Ethnic and sex differences in body fat and visceral and subcutaneous adiposity in children and adolescents. Int J Obes (Lond). 2012;36:1261-9. [Crossref]  [PubMed]  [PMC]
  10. Samaras K, Botelho NK, Chisholm DJ, et al. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity. 2010;18:884-9. [Crossref]  [PubMed]
  11. Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Research and Clinical Practice. 2014;105(2):141-50. [Crossref]  [PubMed]
  12. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87-91. [Crossref]  [PubMed]
  13. Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinology and Metabolism Clinics of North America. 2008;37(3):753-68. [Crossref]  [PubMed]  [PMC]
  14. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. Journal of Lipid Research. 2005;46(11):2347-55. [Crossref]  [PubMed]
  15. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. British Journal of Nutrition. 2004;92(3):347-55. [Crossref]  [PubMed]
  16. Bradley JR. TNF-Mediated inflammatory disease. J Pathol. 2008;214:149-160. [Crossref]  [PubMed]
  17. Wang B, Trayhurn P. Acute and prolonged effects of TNF-α on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Archiv European Journal of Physiology. 2006;452(4):418-27. [Crossref]  [PubMed]
  18. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity- induced insulin resistance. 1996;271(5249):665-8. [Crossref]  [PubMed]
  19. Stenlöf K, Wernstedt I, Fjällman T, Wallenius V, Wallenius K, Jansson JO. Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. J Clin Endocrinol Metab. 2003;88(9):4379-83. [Crossref]  [PubMed]
  20. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43(6):1318-23. [Crossref]  [PubMed]
  21. Fasshauer M, Kralisch S, Klier M, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications. 2003;301(4):1045-50. [Crossref]  [PubMed]
  22. Liu M, Liu F. Transcriptional and post-translational regulation of adiponectin. Biochemical Journal. 2009;425(1):41-52. [Crossref]  [PubMed]
  23. Fumeron F, Aubert R, Siddiq A, et al. Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3- year period: the epidemiologic data on the insulin resistance syndrome prospective study. Diabetes. 2004;53(4):1150-7. [Crossref]  [PubMed]